In-vitro activity of FCE 22101 against respiratory tract pathogens with reference to production of beta-lactamases.

Abstract

FCE 22101 is a new penem with broad antibacterial spectrum, excluding the pseudomonads, and has stability to many beta-lactamases. FCE 22101 and imipenem were very potent against the bacteria studied, including beta-lactamase producing strains, which can be isolated from patients with respiratory tract infections (MIC less than or equal to 8 mg/l). No strains were found to be resistant to FCE 22101. FCE 22101 was rapidly bactericidal and more stable to inactivation by beta-lactamases from Branhamella catarrhalis, Haemophilus influenzae, Enterobacter cloacae and Klebsiella pneumoniae than imipenem and ceftibuten. The other antibiotics tested varied in their activities against the respiratory tract pathogens.

• Authors: K Dornbusch, G Kronvall, E Göransson, E Mörtsell
• Journal: The Journal of antimicrobial chemotherapy (J Antimicrob Chemother) Vol. 23 Suppl C Pg. 31-41 (Mar 1989) ISSN: 0305-7453 [Print] England
• PMID: 2786517 (Publication Type: Journal Article)

Chemical References

• Anti-Bacterial Agents
• Carbapenems
• Cephalosporins
• Imipenem
• ritipenem
• beta-Lactamases
• Ceftibuten

Topics

• Anti-Bacterial Agents (metabolism, pharmacology)
• Bacteria (drug effects, enzymology)
• Carbapenems
• Ceftibuten
• Cephalosporins (pharmacology)
• Imipenem (pharmacology)
• Microbial Sensitivity Tests
• Respiratory Tract Infections (microbiology)
• beta-Lactamases (biosynthesis, metabolism)